Long non‑coding RNA HCG18 facilitates the progression of laryngeal and hypopharyngeal squamous cell carcinoma by upregulating FGFR1 via miR‑133b

Peng,Hongbin; Ge,Pingjiang

doi:10.3892/mmr.2021.12562

Long non‑coding RNA HCG18 facilitates the progression of laryngeal and hypopharyngeal squamous cell carcinoma by upregulating FGFR1 via miR‑133b

Authors:
- Hongbin Peng
- Pingjiang Ge
View Affiliations

Affiliations: Department of Otorhinolaryngology Head and Neck Surgery, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, Guangdong 528400, P.R. China, Department of Otorhinolaryngology Head and Neck Surgery, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510000, P.R. China
Published online on: December 8, 2021 https://doi.org/10.3892/mmr.2021.12562
Article Number: 46
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been reported that long non‑coding RNA HLA complex group 18 (HCG18) is involved in the progression of cancer, acting as an oncogenic gene. The aim of the present study was to investigate the mechanism underlying the action of HCG18 in laryngeal and hypopharyngeal squamous cell carcinoma (LHSCC). The expression levels of HCG18, microRNA (miR)‑133b and fibroblast growth factor receptor 1 (FGFR1) in LHSCC tissues and transfected LHSCC cells were evaluated by reverse transcription‑quantitative PCR or immunohistochemistry. The viability, migration and invasion of transfected LHSCC cells were detected by Cell Counting Kit‑8, wound healing and Transwell assays, respectively. The targeting relationships of HCG18, miR‑133b and FGFR1 were predicted by bioinformatics analysis and confirmed using a dual‑luciferase reporter assay. Moreover, the expression levels of FGFR1, phosphorylated (p)‑PI3K, PI3K, p‑AKT, AKT, p53, Bax and Bcl‑2 in transfected LHSCC cells were measured by western blotting. It was found that the expression levels of HCG18 and FGFR1 were upregulated, but those of miR‑133b were downregulated in LHSCC tissues. Short hairpin RNA (sh) HCG18 and miR‑133b mimic inhibited LHSCC cell viability, while enhancing miR‑133b expression. HCG18 could competitively bind with miR‑133b. Moreover, the miR‑133b inhibitor promoted cell viability, migration, invasion and the expression levels of Bcl‑2, p‑PI3K and p‑AKT, but inhibited the expression levels of p53 and Bax, which were abrogated by shHCG18. miR‑133b could competitively bind with FGFR1, and the miR‑133b mimic decreased the expression level of FGFR1 in transfected LHSCC cells. shFGFR1 promoted the expression levels of p53 and Bax, while inhibiting viability, migration, invasion and Bcl‑2, p‑PI3K and p‑AKT expression in LHSCC cells. In conclusion, the current results indicated that HCG18 facilitated the progression of LHSCC by upregulating FGFR1 via miR‑133b. The present study evaluated the mechanism with regards to the action of HCG18 in LHSCC, and these experimental results may provide novel evidence for targeted therapy of LHSCC.

View Figures

View References

1	Song L, Zhang S, Yu S, Ma F, Wang B, Zhang C, Sun J, Mao X and Wei L: Cellular heterogeneity landscape in laryngeal squamous cell carcinoma. Int J Cancer. 147:2879–2890. 2020. View Article : Google Scholar : PubMed/NCBI
2	Abdeyrim A, He S, Zhang Y, Mamtali G, Asla A, Yusup M and Liu J: Prognostic value of lymph node ratio in laryngeal and hypopharyngeal squamous cell carcinoma: A systematic review and meta-analysis. J Otolaryngol Head Neck Surg. 49:312020. View Article : Google Scholar : PubMed/NCBI
3	Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, et al: NCCN guidelines insights: Head and neck cancers, Version 1.2018. J Natl Compr Canc Netw. 16:479–490. 2018. View Article : Google Scholar : PubMed/NCBI
4	Dietz A, Wiegand S, Kuhnt T and Wichmann G: Laryngeal preservation approaches: Considerations for new selection criteria based on the DeLOS-II trial. Front Oncol. 9:6252019. View Article : Google Scholar : PubMed/NCBI
5	Yang L, Luo D, Yi J, Li L, Zhao Y, Lin M, Guo W, Hu L and Zhou C: Therapy effects of advanced hypopharyngeal and laryngeal squamous cell carcinoma: Evaluated using dual-energy CT quantitative parameters. Sci Rep. 8:90642018. View Article : Google Scholar : PubMed/NCBI
6	Tang XJ, Wang W and Hann SS: Interactions among lncRNAs, miRNAs and mRNA in colorectal cancer. Biochimie. 163:58–72. 2019. View Article : Google Scholar : PubMed/NCBI
7	Zhang Y and Tang L: The application of lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer Drug Discov. 13:292–301. 2018. View Article : Google Scholar : PubMed/NCBI
8	Nandwani A, Rathore S and Datta M: lncRNAs in cancer: Regulatory and therapeutic implications. Cancer Lett. 501:162–171. 2021. View Article : Google Scholar : PubMed/NCBI
9	Taniue K and Akimitsu N: The functions and unique features of lncRNAs in cancer development and tumorigenesis. Int J Mol Sci. 22:6322021. View Article : Google Scholar : PubMed/NCBI
10	Ma P, Li L, Liu F and Zhao Q: HNF1A-induced lncRNA HCG18 facilitates gastric cancer progression by upregulating DNAJB12 via miR-152-3p. Onco Targets Ther. 13:7641–7652. 2020. View Article : Google Scholar : PubMed/NCBI
11	Li S, Wu T, Zhang D, Sun X and Zhang X: The long non-coding RNA HCG18 promotes the growth and invasion of colorectal cancer cells through sponging miR-1271 and upregulating MTDH/Wnt/β-catenin. Clin Exp Pharmacol Physiol. 47:703–712. 2020. View Article : Google Scholar : PubMed/NCBI
12	Li W, Pan T, Jiang W and Zhao H: HCG18/miR-34a-5p/HMMR axis accelerates the progression of lung adenocarcinoma. Biomed Pharmacother. 129:1102172020. View Article : Google Scholar : PubMed/NCBI
13	Li L, Ma TT, Ma YH and Jiang YF: lncRNA HCG18 contributes to nasopharyngeal carcinoma development by modulating miR-140/CCND1 and Hedgehog signaling pathway. Eur Rev Med Pharmacol Sci. 23:10387–10399. 2019.PubMed/NCBI
14	Testa U, Pelosi E, Castelli G and Labbaye C: miR-146 and miR-155: Two key modulators of immune response and tumor development. Noncoding RNA. 3:222017.PubMed/NCBI
15	Xu Z, Huang B, Zhang Q, He X, Wei H and Zhang D: NOTCH1 regulates the proliferation and migration of bladder cancer cells by cooperating with long non-coding RNA HCG18 and microRNA-34c-5p. J Cell Biochem. 120:6596–6604. 2019. View Article : Google Scholar : PubMed/NCBI
16	Georgantas RW, Streicher K, Greenberg SA, Greenlees LM, Zhu W, Brohawn PZ, Higgs BW, Czapiga M, Morehouse CA, Amato A, et al: Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies. Arthritis Rheumatol. 66:1022–1033. 2014. View Article : Google Scholar : PubMed/NCBI
17	Lv L, Li Q, Chen S, Zhang X, Tao X, Tang X, Wang S, Che G, Yu Y and He L: miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L. Exp Cell Res. 385:1115972019. View Article : Google Scholar : PubMed/NCBI
18	Zeng W, Zhu JF, Liu JY, Li YL, Dong X, Huang H and Shan L: miR-133b inhibits cell proliferation, migration and invasion of esophageal squamous cell carcinoma by targeting EGFR. Biomed Pharmacother. 111:476–484. 2019. View Article : Google Scholar : PubMed/NCBI
19	Zhang K, Zhou H, Yan B and Cao X: TUG1/miR-133b/CXCR4 axis regulates cisplatin resistance in human tongue squamous cell carcinoma. Cancer Cell Int. 20:1482020. View Article : Google Scholar : PubMed/NCBI
20	Xia L, Li S, Liu Y, Huang Y, Ni B, Wan L, Mei H, Li X, Cai Z and Li Z: NDNF inhibits the migration and invasion of human renal cancer cells through epithelial-mesenchymal transition. Oncol Lett. 17:2969–2975. 2019.PubMed/NCBI
21	Bian Q: Circular RNA PVT1 promotes the invasion and epithelial-mesenchymal transition of breast cancer cells through serving as a competing endogenous RNA for miR-204-5p. Onco Targets Ther. 12:11817–11826. 2019. View Article : Google Scholar : PubMed/NCBI
22	Song X, Luo X, Gao Q, Wang Y, Gao Q and Long W: Dysregulation of lncRNAs in placenta and pathogenesis of preeclampsia. Curr Drug Targets. 18:1165–1170. 2017. View Article : Google Scholar : PubMed/NCBI
23	Lou W, Ding B, Zhong G, Du C, Fan W and Fu P: Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer. Aging (Albany NY). 11:11416–11439. 2019. View Article : Google Scholar : PubMed/NCBI
24	Zhang X, Tang X, Liu K, Hamblin MH and Yin KJ: Long noncoding RNA malat1 regulates cerebrovascular pathologies in ischemic stroke. J Neurosci. 37:1797–1806. 2017. View Article : Google Scholar : PubMed/NCBI
25	Mamoori A, Gopalan V and Lam AK: Role of miR-193a in cancer: Complexity and factors control the pattern of its expression. Curr Cancer Drug Targets. 18:618–628. 2018. View Article : Google Scholar : PubMed/NCBI
26	Malchers F, Ercanoglu M, Schütte D, Castiglione R, Tischler V, Michels S, Dahmen I, Brägelmann J, Menon R, Heuckmann JM, et al: Mechanisms of primary drug resistance in FGFR1-amplified lung cancer. Clin Cancer Res. 23:5527–5536. 2017. View Article : Google Scholar : PubMed/NCBI
27	Haq F, Sung YN, Park I, Kayani MA, Yousuf F, Hong SM and Ahn SM: FGFR1 expression defines clinically distinct subtypes in pancreatic cancer. J Transl Med. 16:3742018. View Article : Google Scholar : PubMed/NCBI
28	Chen S, Qiu Y, Guo P, Pu T, Feng Y and Bu H: FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis. Oncol Lett. 15:8206–8214. 2018.PubMed/NCBI
29	Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD and Parker AL: Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fiber knob domain and their evaluation as targeted cancer therapies. Hum Gene Ther. 26:320–329. 2015. View Article : Google Scholar : PubMed/NCBI
30	Jiao J, Zhao X, Liang Y, Tang D and Pan C: FGF1-FGFR1 axis promotes tongue squamous cell carcinoma (TSCC) metastasis through epithelial-mesenchymal transition (EMT). Biochem Biophys Res Commun. 466:327–332. 2015. View Article : Google Scholar : PubMed/NCBI
31	Kim EK, Cho YA, Koh YW, Shin HA, Cho BC and Yoon SO: Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma. BMC Cancer. 20:3482020. View Article : Google Scholar : PubMed/NCBI
32	Murugan AK: Special issue: PI3K/Akt signaling in human cancer. Semin Cancer Biol. 59:1–2. 2019. View Article : Google Scholar : PubMed/NCBI
33	Narayanankutty A: PI3K/Akt/mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidence. Curr Drug Targets. 20:1217–1226. 2019. View Article : Google Scholar : PubMed/NCBI
34	Khan H, Reale M, Ullah H, Sureda A, Tejada S, Wang Y, Zhang ZJ and Xiao J: Anti-cancer effects of polyphenols via targeting p53 signaling pathway: Updates and future directions. Biotechnol Adv. 38:1073852020. View Article : Google Scholar : PubMed/NCBI
35	Chen GY and Ruan L: Downregulation Of microRNA-133b and its clinical value in non-small cell lung cancer. Onco Targets Ther. 12:9421–9434. 2019. View Article : Google Scholar : PubMed/NCBI
36	Liu W, Zhan J, Zhong R, Li R, Sheng X, Xu M, Lu Z and Zhang S: Upregulation of long noncoding RNA_GAS5 suppresses cell proliferation and metastasis in laryngeal cancer via regulating PI3K/AKT/mTOR signaling pathway. Technol Cancer Res Treat. 20:15330338219900742021. View Article : Google Scholar : PubMed/NCBI
37	Zhang B, Wu J, Guo P, Wang Y, Fang Z, Tian J, Yu Y, Teng W, Luo Y and Li Y: Down-regulation of SREBP via PI3K/AKT/mTOR pathway inhibits the proliferation and invasion of non-small-cell lung cancer cells. Onco Targets Ther. 13:8951–8961. 2020. View Article : Google Scholar : PubMed/NCBI
38	Bumbat M, Wang M, Liang W, Ye P, Sun W and Liu B: Effects of Me2SO and trehalose on the cell viability, proliferation, and Bcl-2 family gene (BCL-2, BAX, and BAD) expression in cryopreserved human breast cancer cells. Biopreserv Biobank. 18:33–40. 2020. View Article : Google Scholar : PubMed/NCBI
39	Hong B, van den Heuvel AP, Prabhu VV, Zhang S and El-Deiry WS: Targeting tumor suppressor p53 for cancer therapy: Strategies, challenges and opportunities. Curr Drug Targets. 15:80–89. 2014. View Article : Google Scholar : PubMed/NCBI